<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28851/preferred-agents-during-treatment-of-2nd-line-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Preferred Agents During Treatment of 2nd Line RCC

Name: Preferred Agents During Treatment of 2nd Line RCC
Uploaded: 2019-06-25T08:13:21
Duration: 51 s
Description: Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.

00:00:51

Don

3 years 178 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28851/preferred-agents-during-treatment-of-2nd-line-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28851/preferred-agents-during-treatment-of-2nd-line-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28851/preferred-agents-during-treatment-of-2nd-line-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28851?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190625201321_0732/video_190625201321_0732.jpg?cache=15669161731678829655">Preferred Agents During Treatment of 2nd Line RCC</a>

Link (BBCode):

[url=https://oncologytube.com/v/28851?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190625201321_0732/video_190625201321_0732.jpg?cache=15669161731678829655[/img]Preferred Agents During Treatment of 2nd Line RCC[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Immunotherapy

Description:

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.